Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Esgliteo
- Development stage
- Phase 4
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Esgliteo is a fixed-dose combination (FDC) therapy containing the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin and the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin. Developed through a partnership between Boehringer Ingelheim and Eli Lilly, it is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin reduces blood glucose by inhibiting renal reabsorption of glucose in the proximal tubule, leading to its excretion in the urine. Linagliptin works by inhibiting the enzyme DPP-4, which slows the degradation of incretin hormones such as GLP-1 and GIP, thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. Esgliteo is the brand name specifically used in the South Korean market, while the same combination is marketed as Glyxambi in the United States and other international regions.
- Brand names
- EsgliteoGlyxambi
- Other names
- empagliflozin + linagliptinempagliflozin/linagliptin
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on Esgliteo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Esgliteo.